PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin (PER977)
Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single, Hourly-Repeating, Escalating Doses of PER977 Following a Single Subcutaneous Dose of Enoxaparin
Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Listed as NCT02206100, this PHASE1/PHASE2 trial focuses on Healthy and remains completed. Sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc., it has been updated 10 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Jun 2020 [monthly]
Completed PHASE1_PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Oct 2017 — Dec 2017 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .